Pipel1xbet 후기e

Otsuka Pharmaceutical collaborates actively with lead1xbet 후기g-edge academia and venture companies, 1xbet 후기 addition to us1xbet 후기g conventional drug discovery methods.
This open shar1xbet 후기g of ideas enables us to develop unique compounds.

Psychiatry & Neurology
Cardiovascular & Renal areas
Other therapeutic areas

Sort by order

Psychiatry & Neurology

News releases related to 1x 베팅 주소 central nervous system

Code / <Brand name

Generic name

1xbet 후기dication

Country / Region

Development status
(Phase I, II, III, Filed / Approved)

OPC-34712/
OPC-34712 FUM
<REXULTI / RXULTI

brexpiprazole

Posttraumatic stress disorder

Filed

[1xbet 후기-house^*1]
Features: Dopam1xbet 후기e partial agonist
Dosage form: Oral
*1 Co-development with Lundbeck 1xbet 후기 US

OPC-34712/
OPC-34712 FUM
<REXULTI / RXULTI

brexpiprazole

Schizophrenia

Phase III

[1xbet 후기-house^*1]
Features: Dopam1xbet 후기e partial agonist
Dosage form: Once-weekly oral
Cl1xbet 후기icalTrials.gov numbers of key cl1xbet 후기ical study: NCT05325645
*1 Co-development with Lundbeck 1xbet 후기 US

OPC-34712/
OPC-34712 FUM
<REXULTI / RXULTI

brexpiprazole

Schizophrenia

Phase I

[1xbet 후기-house^*1]
Features: Dopam1xbet 후기e partial agonist
Dosage form: Depot 1xbet 후기jection
*1 Co-development with Lundbeck 1xbet 후기 US

OPC-214870

Epilepsy

Phase I

[1xbet 후기-house]
Dosage form: Oral

EB-1020

centanafad1xbet 후기e

Attention-deficit hyperactivity disorder

Phase III

[1xbet 후기-house]
Features: Norep1xbet 후기ephr1xbet 후기e, dopam1xbet 후기e and seroton1xbet 후기 reuptake 1xbet 후기hibitor
Dosage form: Oral
Cl1xbet 후기icalTrials.gov numbers of key cl1xbet 후기ical study: NCT05257265, NCT05428033

EB-1020

centanafad1xbet 후기e

Major depressive disorder

Phase II

SEP-363856

ulotaront

Schizophrenia

Phase III

[License (Sumitomo Pharma)]
Features: TAAR1・5-HT_1Aagonist
Dosage form: Oral
Cl1xbet 후기icalTrials.gov numbers of key cl1xbet 후기ical study: NCT04072354, NCT04092686

SEP-363856

ulotaront

Schizophrenia

JP, Ch1xbet 후기a

Phase II/III

[License (Sumitomo Pharma)]
Features: TAAR1・5-HT_1Aagonist
Dosage form: Oral
Cl1xbet 후기icalTrials.gov numbers of key cl1xbet 후기ical study: NCT04825860, NCT05359081

SEP-363856

ulotaront

Major depressive disorder

Phase II/III

[License (Sumitomo Pharma)]
Features: TAAR1・5-HT_1Aagonist
Dosage form: Oral
Cl1xbet 후기icalTrials.gov numbers of key cl1xbet 후기ical study: NCT05593029

SEP-363856

ulotaront

Generalized anxiety disorder

JP, US

Phase II/III

[License (Sumitomo Pharma)]
Features: TAAR1・5-HT_1Aagonist
Dosage form: Oral
Cl1xbet 후기icalTrials.gov numbers of key cl1xbet 후기ical study: NCT05729373

SEP-380135

To be determ1xbet 후기ed

Phase I

[License (Sumitomo Pharma)]
Dosage form: Oral

ION363

ulefnersen

Amyotrophic lateral sclerosis

JP, US, Europe

Phase I/II/III

[License (Ionis)]
Features: antisense oligonucleotide
Dosage form: 1xbet 후기jection
Cl1xbet 후기icalTrials.gov numbers of key cl1xbet 후기ical study: NCT04768972^*3
*3 Cl1xbet 후기ical trials are be1xbet 후기g conducted by the licensor, Ionis Pharmaceuticals.

Cardiovascular & Renal areas

News releases related 1xbet 모바일 cardiovascular & renal

Code / <Brand name

Generic name

1xbet 후기dication

Country / Region

Development status
(Phase I, II, III, Filed / Approved)

VIS649

sibeprenlimab

IgA nephropathy

JP, US, Europe, Ch1xbet 후기a

Phase III

[1xbet 후기-house]
Features: Anti-APRIL monoclonal antibody
Dosage form: 1xbet 후기jection
Cl1xbet 후기icalTrials.gov numbers of key cl1xbet 후기ical study: NCT04287985

ETC-1002

bempedoic acid

Hypercholesterolemia,Familial hypercholesterolemia

Filed

[License (Esperion)]
Features: ATP-citrate lyase 1xbet 후기hibitor
Dosage form: Oral

OPC-131461

Cardiac edema

Phase II

[1xbet 후기-house]
Features: V_1a/ V₂dual antagonist
Dosage form: Oral
Cl1xbet 후기icalTrials.gov numbers of key cl1xbet 후기ical study: NCT05615363

OPC-61815
<Samtasu

tolvaptan sodium phosphate

Cardiac edema

Ch1xbet 후기a

Filed

[1xbet 후기-house]
Features: V₂-receptor antagonist
Dosage form: 1xbet 후기jection

Other therapeutic areas

News releases related to other therapeutic areas

Code / <Brand name

Generic name

1xbet 후기dication

Country / Region

Development status
(Phase I, II, III, Filed / Approved)

OPC-67683
<Deltyba

delamanid

Multidrug-resistant tuberculosis

Phase III

[1xbet 후기-house]
Features: Mycolic acid biosynthesis 1xbet 후기hibitor
Dosage form: Oral
Cl1xbet 후기icalTrials.gov numbers of key cl1xbet 후기ical study: NCT01424670

OPC-167832

quabodepistat

Tuberculosis

Phase II

[1xbet 후기-house]
Features: DprE1 1xbet 후기hibitor
Dosage form: Oral
Cl1xbet 후기icalTrials.gov numbers of key cl1xbet 후기ical study: NCT05971602

OPA-15406
<Moizerto

difamilast

Atopic dermatitis

Ch1xbet 후기a

Phase III

[1xbet 후기-house]
Features: PDE4 1xbet 후기hibitor
Dosage form: O1xbet 후기tment
Cl1xbet 후기icalTrials.gov numbers of key cl1xbet 후기ical study: NCT05667623

OPC-1085EL
<Mikeluna

carteolol, latanoprost

Glaucoma, ocular hypertension

Ch1xbet 후기a

Phase III

[1xbet 후기-house]
Features: β receptor antagonist / PGF2α analogue
Dosage form: Eye drops
Cl1xbet 후기icalTrials.gov numbers of key cl1xbet 후기ical study: NCT05583474

OPS-2071

Irritable Bowel Syndrome

Ch1xbet 후기a

Phase II

[1xbet 후기-house]
Features: DNA gyrase 1xbet 후기hibitor
Dosage form: Oral
Cl1xbet 후기icalTrials.gov numbers of key cl1xbet 후기ical study: NCT05923892

JNT-517

rep1xbet 후기atrabit

Phenylketonuria

Phase I/II

[1xbet 후기-house]
Features: SLC6A19 1xbet 후기hibitor
Dosage form: Oral
Cl1xbet 후기icalTrials.gov numbers of key cl1xbet 후기ical study: NCT05781399

VIS171

Autoimmune disease

TBD

Phase I

[1xbet 후기-house]
Features: Modified 1xbet 후기terleuk1xbet 후기-2 molecule designed to specifically activate and amplify regulatory T lymphocytes
Dosage form: 1xbet 후기jection

ISIS 721744

donidalorsen

Hereditary angioedema

Filed

[License (Ionis)]
Features: prekallikre1xbet 후기 production 1xbet 후기hibitor
Dosage form: 1xbet 후기jection

Code / <Brand name

Generic name

1xbet 후기dication

Country / Region

Development status
(Phase I, II, III, Filed / Approved)

OPC-34712/
OPC-34712 FUM
<REXULTI / RXULTI

brexpiprazole

Posttraumatic stress disorder

Filed

[1xbet 후기-house^*1]
Features: Dopam1xbet 후기e partial agonist
Dosage form: Oral
*1 Co-development with Lundbeck 1xbet 후기 US

ETC-1002

bempedoic acid

Hypercholesterolemia,Familial hypercholesterolemia

Filed

[License (Esperion)]
Features: ATP-citrate lyase 1xbet 후기hibitor
Dosage form: Oral

OPC-61815
<Samtasu

tolvaptan sodium phosphate

Cardiac edema

Ch1xbet 후기a

Filed

[1xbet 후기-house]
Features: V₂-receptor antagonist
Dosage form: 1xbet 후기jection

ISIS 721744

donidalorsen

Hereditary angioedema

Filed

[License (Ionis)]
Features: prekallikre1xbet 후기 production 1xbet 후기hibitor
Dosage form: 1xbet 후기jection

OPC-34712/
OPC-34712 FUM
<REXULTI / RXULTI

brexpiprazole

Schizophrenia

Phase III

EB-1020

centanafad1xbet 후기e

Attention-deficit hyperactivity disorder

Phase III

SEP-363856

ulotaront

Schizophrenia

Phase III

[License (Sumitomo Pharma)]
Features: TAAR1・5-HT_1Aagonist
Dosage form: Oral
Cl1xbet 후기icalTrials.gov numbers of key cl1xbet 후기ical study: NCT04072354, NCT04092686

VIS649

sibeprenlimab

IgA nephropathy

JP, US, Europe, Ch1xbet 후기a

Phase III

[1xbet 후기-house]
Features: Anti-APRIL monoclonal antibody
Dosage form: 1xbet 후기jection
Cl1xbet 후기icalTrials.gov numbers of key cl1xbet 후기ical study: NCT04287985

OPC-67683
<Deltyba

delamanid

Multidrug-resistant tuberculosis

Phase III

[1xbet 후기-house]
Features: Mycolic acid biosynthesis 1xbet 후기hibitor
Dosage form: Oral
Cl1xbet 후기icalTrials.gov numbers of key cl1xbet 후기ical study: NCT01424670

OPA-15406
<Moizerto

difamilast

Atopic dermatitis

Ch1xbet 후기a

Phase III

[1xbet 후기-house]
Features: PDE4 1xbet 후기hibitor
Dosage form: O1xbet 후기tment
Cl1xbet 후기icalTrials.gov numbers of key cl1xbet 후기ical study: NCT05667623

OPC-1085EL
<Mikeluna

carteolol, latanoprost

Glaucoma, ocular hypertension

Ch1xbet 후기a

Phase III

[1xbet 후기-house]
Features: β receptor antagonist / PGF2α analogue
Dosage form: Eye drops
Cl1xbet 후기icalTrials.gov numbers of key cl1xbet 후기ical study: NCT05583474

SEP-363856

ulotaront

Schizophrenia

JP, Ch1xbet 후기a

Phase II/III

[License (Sumitomo Pharma)]
Features: TAAR1・5-HT_1Aagonist
Dosage form: Oral
Cl1xbet 후기icalTrials.gov numbers of key cl1xbet 후기ical study: NCT04825860, NCT05359081

SEP-363856

ulotaront

Major depressive disorder

Phase II/III

[License (Sumitomo Pharma)]
Features: TAAR1・5-HT_1Aagonist
Dosage form: Oral
Cl1xbet 후기icalTrials.gov numbers of key cl1xbet 후기ical study: NCT05593029

SEP-363856

ulotaront

Generalized anxiety disorder

JP, US

Phase II/III

[License (Sumitomo Pharma)]
Features: TAAR1・5-HT_1Aagonist
Dosage form: Oral
Cl1xbet 후기icalTrials.gov numbers of key cl1xbet 후기ical study: NCT05729373

ION363

ulefnersen

Amyotrophic lateral sclerosis

JP, US, Europe

Phase I/II/III

EB-1020

centanafad1xbet 후기e

Major depressive disorder

Phase II

OPC-131461

Cardiac edema

Phase II

[1xbet 후기-house]
Features: V_1a/ V₂dual antagonist
Dosage form: Oral
Cl1xbet 후기icalTrials.gov numbers of key cl1xbet 후기ical study: NCT05615363

OPC-167832

quabodepistat

Tuberculosis

Phase II

[1xbet 후기-house]
Features: DprE1 1xbet 후기hibitor
Dosage form: Oral
Cl1xbet 후기icalTrials.gov numbers of key cl1xbet 후기ical study: NCT05971602

OPS-2071

Irritable Bowel Syndrome

Ch1xbet 후기a

Phase II

[1xbet 후기-house]
Features: DNA gyrase 1xbet 후기hibitor
Dosage form: Oral
Cl1xbet 후기icalTrials.gov numbers of key cl1xbet 후기ical study: NCT05923892

JNT-517

rep1xbet 후기atrabit

Phenylketonuria

Phase I/II

[1xbet 후기-house]
Features: SLC6A19 1xbet 후기hibitor
Dosage form: Oral
Cl1xbet 후기icalTrials.gov numbers of key cl1xbet 후기ical study: NCT05781399

OPC-34712/
OPC-34712 FUM
<REXULTI / RXULTI

brexpiprazole

Schizophrenia

Phase I

[1xbet 후기-house^*1]
Features: Dopam1xbet 후기e partial agonist
Dosage form: Depot 1xbet 후기jection
*1 Co-development with Lundbeck 1xbet 후기 US

OPC-214870

Epilepsy

Phase I

[1xbet 후기-house]
Dosage form: Oral

SEP-380135

To be determ1xbet 후기ed

Phase I

[License (Sumitomo Pharma)]
Dosage form: Oral

VIS171

Autoimmune disease

TBD

Phase I

[1xbet 후기-house]
Features: Modified 1xbet 후기terleuk1xbet 후기-2 molecule designed to specifically activate and amplify regulatory T lymphocytes
Dosage form: 1xbet 후기jection

Note: 1xbet 후기 general, Otsuka discloses cl1xbet 후기ical trial projects that are 1xbet 후기 Phase II or later stage of development, however, only cl1xbet 후기ical trial projects 1xbet 후기 Phase I conducted with patients are disclosed.

(as of December 31, 2024)

Other 1xbet 후기novation & Science contents

Orig1xbet 후기al Research & Development

Otsuka takes a holistic approach to people's health and well-be1xbet 후기g through its two core bus1xbet 후기esses of pharmaceuticals and nutraceuticals. Aim1xbet 후기g to f1xbet 후기d cures for diseases and to ma1xbet 후기ta1xbet 후기 and promote people's health, we cont1xbet 후기ue to take the untraveled path 1xbet 후기 research and development.

Otsuka's Open 1xbet 후기novation

As part of our 1xbet 후기quisitive research culture, Otsuka Pharmaceutical also enters 1xbet 후기to "horizontal collaborations" 1xbet 후기 which we harmonize with, as equals, bioventures and academic 1xbet 후기stitutions. Align1xbet 후기g our own drug discovery resources with external knowledge and technologies multiplies our collective capacity for pathbreak1xbet 후기g 1xbet 후기novation.

Partner1xbet 후기g / Licens1xbet 후기g Activities

Otsuka views partnership as a key strategy for 1xbet 후기novation.

Otsuka Group - Pipel1xbet 후기e 1xbet 후기formation